Steglatro

Quote
anonymous said:
The pollster is true about the ADA and Steglatro. Steglatro dominated the discussions at the ADA and all the SGLT2 companies were in discussion as to how to stop the Steglatro growth train. Steglatro is revolutionizing the treatment of Type 2 diabetes. Take a look at the latest Gator numbers and you can easily see why the competitors are in awe of what this blockbuster is doing and will continue to do. Congratulations Merck
Click to expand...

Were any of you even at ADA 2019? Stagnatro was barely mentioned outside of Merck’s booth area. Invokana was the SGLT2 that stole the show. While oral semaglutide took the innovation in diabetes prize. And now Farxiga is hitting it big. Steglatro has nothing going for it, no CV risk/ death reduction, no CKD reduction, no nothing, just glycemic control (with diet and exercise(!)). Wouldn’t be surprised if they sold the diabetes franchise to Sanofi. But really, Steglatro is a big fat nothing
 






anonymous said:
Were any of you even at ADA 2019? Stagnatro was barely mentioned outside of Merck’s booth area. Invokana was the SGLT2 that stole the show. While oral semaglutide took the innovation in diabetes prize. And now Farxiga is hitting it big. Steglatro has nothing going for it, no CV risk/ death reduction, no CKD reduction, no nothing, just glycemic control (with diet and exercise(!)). Wouldn’t be surprised if they sold the diabetes franchise to Sanofi. But really, Steglatro is a big fat nothing
Click to expand...
Steglatro has a tremendous future. All that is stated here is clearly a class effect and Merck knows how to sell diabetic drugs better than anyone. Watch the next Gator data for Steglatro.
 






anonymous said:
Steglatro has a tremendous future. All that is stated here is clearly a class effect and Merck knows how to sell diabetic drugs better than anyone. Watch the next Gator data for Steglatro.
Click to expand...
I just got my latest numbers on Steglatro. What a week. Now Jardiance is behind Steglatro. It took longer than I thought to overtake Jardiance. Hopefully others can join me!
 


















This has to be the funniest thread EVER! You can just picture the Merck leadership saying all of this on conference calls and to the reps....the only access for Steglatro is on Medicaid and they are having trouble giving it away there! Not even Medicaid patients want Steglatro! HAHAHAHAHAHA. Thanks for the morning laugh.
 






Steglatro has tremendous formulary status. Jardiance, Farxiga, and all the other SGLT2s have had special meetings to get a strategy against the rise of Steglatro. Unfortunately they are losing and Steglatro is winning big!
 
















































Top Bottom
Back
Quote